Print Page    Close Window

2017 Press Releases

Keyword Search
 
2017 | 2016
DateTitle  
06/28/17Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients
Gemcabene achieves primary endpoint for LDL cholesterol in phase 2b HoFH trial Company to host conference call at 4:30 pm ET today LIVONIA, Mich., June 28, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced top-line data on the LDL-C primary endpoint from the completed open label Phase 2b COBALT-1 trial.  COBALT-1 evaluated gemcabene in homozygous familial hypercholesterolemia (HoFH) patients who are on stable maximally tolerated lipid-lowering therapies to a... 
Download PDFPrinter Friendly Version
06/01/17Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference
LIVONIA, Mich., June 01, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at LD Micro Invitational, taking place June 6-7 in Los Angeles, California, and at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9, 2017, in New York City. ... 
Download PDFPrinter Friendly Version
05/30/17Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch
LIVONIA, Mich., May 30, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP) announced today that Mina Sooch, President, CEO, and Director of the Company has resigned for personal reasons effective May 23, 2017.  Dr. Steven Gullans, a member of the Gemphire Therapeutics Board of Directors, has been named Interim President and Chief Executive Officer until a search for his replacement is completed. “On behalf of the Board of Directors of Gemphire Therapeutics, we thank Mina for ... 
Download PDFPrinter Friendly Version
05/09/17Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update
LIVONIA, Mich., May 09, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced financial results for the first quarter ended March 31, 2017, and provided a corporate update. “The first quarter was a very productive start to 2017 for Gemphire, highlighted by continued progress in developing gemcabene, our fi... 
Download PDFPrinter Friendly Version
05/04/17Gemphire to Host Key Opinion Leader Lunch on the Evolving NASH Landscape
Live Webcast with Slides on May 9th at 12 noon EDT LIVONIA, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, will host a key opinion leader (KOL) lunch to discuss the evolving nonalcoholic steatohepatitis (NASH) landscape in New York City on Tuesday, May 9 from 12:00pm - 1:30pm Eastern Time. The meeti... 
Download PDFPrinter Friendly Version
05/01/17Gemphire to Present at ATVB|PVD 2017 Scientific Sessions
Company Plans to Announce Q1-2017 Financial Results on May 9 LIVONIA, Mich., May 01, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that it will present a poster on gemcabene’s mechanism of action based on recent preclinical findings at the Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2017 Scientific Sessions, taking place in Minneapolis May 4-6, 2017.   The company also plans to release its financial results fo... 
Download PDFPrinter Friendly Version
03/29/17Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
LIVONIA, Mich., March 29, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that on March 28, 2017, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Gemphire’s Inducement Plan, as a material inducement to one individual entering into employment with Gemphire.  The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public annou... 
Download PDFPrinter Friendly Version
03/21/17Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization
Gemcabene Demonstrated a Doubling of the Glucose Disposal Rate and 40% LDL-C Reduction LIVONIA, Mich., March 21, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, announced today the results of a Phase 2 trial that investigated insulin sensitization and LDL-C lowering by gemcabene in non-diabetic, obese patients. The re... 
Download PDFPrinter Friendly Version
03/16/17Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event
LIVONIA, Mich., March 16, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at the Oppenheimer 27th Annual Healthcare Conference, taking place March 21-22 at the Westin New York Grand Central Hotel, and will also present at the 1st Annual H.C. Wainwright NAS... 
Download PDFPrinter Friendly Version
03/15/17Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update
Announces Date for 2017 Annual Meeting of Stockholders Conference Call and Live Webcast, Today at 4:30 Eastern Time LIVONIA, Mich., March 15, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced financial results for the fourth quarter and full fiscal year ended December 31, 2016 and provided a corporat... 
Download PDFPrinter Friendly Version
03/13/17Gemphire Therapeutics to Report Fiscal Year End 2016 Financial Results on Wednesday, March 15
Poster on Phase 2 Trial Investigating Effect of Gemcabene on Insulin Sensitization to be Presented at ACC Meeting on March 19 LIVONIA, Mich., March 13, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH, will release fiscal year ended December 31, 2016 financial results on Wednesday, March 15 after the market close, and host a conferen... 
Download PDFPrinter Friendly Version
03/10/17Gemphire Therapeutics Announces $12.5 Million Financing
LIVONIA, Mich., March 10, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH, today announced that it has entered into a securities purchase agreement for a private placement with a select group of accredited investors. The private placement will consist of 1,324,256 units sold at a price of $9.47 per unit for gross proceeds of approxim... 
Download PDFPrinter Friendly Version
02/02/17Gemphire Therapeutics to Participate in the Canaccord Genuity Rare Disease and Biopharma 1 on 1 Day and the RBC Capital Markets Global Healthcare Conference
LIVONIA, Mich., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH, today announced that its senior management team will participate in two investor conferences in New York City during the month of February.   Mina Sooch, President and CEO, will be attending the Canaccord Genuity Rare Disease and Biopharma 1x1 Day and will b... 
Download PDFPrinter Friendly Version
01/30/17Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial
Gemcabene 600 mg Decreased Mean LDL-C by 28% on Top of Maximum Statin Lipid-Lowering Therapy in HoFH Patients LIVONIA, Mich., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced interim data on the LDL-C primary endpoint from the ongoing open label COBALT-1 trial.  COBALT-1 is investigating gemcabene in homozygous familial hypercholesterolemia (HoFH) patients diagnosed by genetic confirmation or a clinical diagnosis to assess the efficacy, safety, and to... 
Download PDFPrinter Friendly Version
01/18/17Gemphire Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LIVONIA, Mich., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that on January 16, 2017, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Gemphire’s Inducement Plan, as a material inducement to three individuals entering into employment with Gemphire.  The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public... 
Download PDFPrinter Friendly Version
01/09/17Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study
Company Plans to Launch a Clinical Development Program in NAFLD/NASH in 2017 based on Gemcabene’s Lipid-Lowering and Inflammation Mechanism of Action LIVONIA, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced expanded utility for gemcabene with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of nonalcoholic steatohepatitis (NASH).  Gemphire plans to initiate clinical development of g... 
Download PDFPrinter Friendly Version
01/05/17Gemphire Therapeutics Provides Clinical Update
Enrollment in the ROYAL-1 Clinical Trial Investigating Gemcabene in Hypercholesterolemia Is Ahead of Plan and Expected to be Completed This Month – Data Expected in the Third Quarter of 2017 Interim Data from the COBALT-1 Trial for Homozygous Familial Hypercholesterolemia (HoFH) Patients Expected the Week of January 30, 2017 INDIGO-1 Trial Commenced for Severe Hypertriglyceridemia (SHTG) Patients LIVONIA, Mich., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a... 
Download PDFPrinter Friendly Version